Quince Therapeutics, Inc. Common Stock
$29.48
$2.47 (+9.14%)
$27.20Day Range$30.00
Key Statistics
Market Cap
$29.98M
Shares Outstanding
1.0M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
May 9, 2019
Round Lot
100
Locale
US
Trading Data
Day Open
$27.20
Day High
$30.00
Day Low
$27.20
Volume
48.8K
VWAP
$28.73
Prev Close
$27.01
Transactions
--
Acc. Volume
--
About Quince Therapeutics, Inc. Common Stock
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 283638 employees611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO, CA, 94080415-910-5717IPO May 9, 2019US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001662774
- Composite FIGI
- BBG00BTK1DT8
- Share Class FIGI
- BBG00BTK1DS9
- Ticker Root
- QNCX
- SIC Code
- 2836
About Quince Therapeutics, Inc. Common Stock (QNCX) Stock
Quince Therapeutics, Inc. Common Stock (QNCX) closed the 2026-09-18 session at $29.48, up 9.14% versus the previous close (+2.47). The stock opened at $27.20 and traded between $27.20 and $30.00 during that session. Session trading volume was 49K shares. The volume-weighted average price (VWAP) is $28.73.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
Quince Therapeutics, Inc. Common Stock has a market capitalization of $30.0 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. QNCX is listed on the XNAS exchange. The company employs approximately 38 people. Quince Therapeutics, Inc. Common Stock is headquartered in SOUTH SAN FRANCISCO, CA. The recorded listing date is 2019-05-09.
On this page you can find market QNCX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.